IFNB1 and Down syndrome: The results of a recent multicenter cohort study even support the preference of newer disease-modifying drugs, including dimethyl fumarate, fingolimod, teriflunomide, natalizumab, rituximab, ocrelizumab, and alemtuzumab, over beta-interferon or glatiramer acetate for the initial treatment of pediatric patients and clinically isolated syndrome (25).